MeiraGTx Holdings PLC
NASDAQ:MGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MeiraGTx Holdings PLC
Cash Interest Paid
MeiraGTx Holdings PLC
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MeiraGTx Holdings PLC
NASDAQ:MGTX
|
Cash Interest Paid
$11m
|
CAGR 3-Years
222%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Interest Paid
$3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Interest Paid
$1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Interest Paid
$12.4m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Interest Paid
$41.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
MeiraGTx Holdings PLC
Glance View
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 287 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The firm has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.
See Also
What is MeiraGTx Holdings PLC's Cash Interest Paid?
Cash Interest Paid
11m
USD
Based on the financial report for Dec 31, 2025, MeiraGTx Holdings PLC's Cash Interest Paid amounts to 11m USD.
What is MeiraGTx Holdings PLC's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
222%
Over the last year, the Cash Interest Paid growth was -8%. The average annual Cash Interest Paid growth rates for MeiraGTx Holdings PLC have been 222% over the past three years .
